NCT07318129Recruiting
Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis
Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis (iPROACT-MS)
Source: ClinicalTrials.gov · Last updated 28 Jan 2026
Brief summary (registry, in English)
This study, iPROACT-MS, is part of the iPROACT group of clinical trials aiming to investigate the effects of oral supplementation with indole-3-propionic acid (IPA) in humans. IPA is naturally produced as a gut bacterial metabolite with the amino acid tryptophan as substrate. The primary aim of iPROACT-MS is to investigate whether patients with relapsing-remitting multiple sclerosis (RRMS) can benefit from supplementation with IPA. The hypothesis is that supplementation with IPA will protect against MS-related disease activity, neurodegeneration and metabolic abnormalities. Secondary, iPROACT-MS aims at elucidating the complex relationships between lifestyle, gut microbial factors, inflammation, oxidative stress, metabolic health, MS disease severity and MS disease activity.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 220 (estimated)
- First submitted
- 23 Nov 2025
- Start date
- 26 Jan 2026
- Primary completion date
- 15 Jul 2028
- Lead sponsor
- Glostrup University Hospital, Copenhagen
- Diseases
- Multiple sclerosis
- NCT number
- NCT07318129
What you commit to
- Study type: Interventional
- Planned participants: 220
- From 26 Jan 2026 to the primary completion date, 15 Jul 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Haematopoietic stem cell transplantation
- Current or past treatment with non-MS related treatments deemed to be relevant
Other illness
- Active malignancy
- Diagnosis of Crohn's disease and ulcerative colitis
- People with MR contraindications:
- Severe claustrophobia
- Incompatible implants/ foreign objects, including implanted pacemakers, heart valve prostheses, prostheses in the middle ear, implanted devices (e.g., insulin pump), metal debris, e.g., metal splinters in the eyes, miscellaneous shunts and catheters, metal clips from operations
Other
- Other comorbidities deemed to be relevant
- Pregnancy or lactation
Who the study is looking for
- Women and men ≥18 and ≤65 years of age
- Diagnosed with RRMS according to the 2017 McDonald criteria (or newer updates)
- Routinely treated and monitored for MS
- Speak and read Danish
- Deemed physically and mentally able to participate in this study
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Glostrup Hospital Coordinator of this site? Confirm its status | Glostrup Municipality | Denmark | Recruiting |
Related publications
- Gut microbiota and gut-derived metabolites in defining multiple sclerosis phenotypic continuum.Front Immunol · 2026 · PMID 42459649
This page is information, not medical advice. Discuss any trial with your doctor.